Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma.

导出 OA

翻译打印收藏纠错

第一作者： Ravi,Potluri

第一单位： SmartAnalyst Inc., New York, NY USA.

作者： Ravi,Potluri ^[1] ; Sandip,Ranjan ^[2] ; Hitesh,Bhandari ^[2] ; Helen,Johnson ^[3] ; Andriy,Moshyk ^[4] ; Srividya,Kotapati ^[4]

作者单位： SmartAnalyst Inc., New York, NY USA. ^[1] SmartAnalyst India Pvt. Ltd., Gurgaon, India. ^[2] 3Bristol-Myers Squibb, Uxbridge, UK. ^[3] 4Bristol-Myers Squibb, Lawrence Township, NJ USA. ^[4]

关键词 Advanced melanoma CheckMate 067 Healthcare cost comparison Ipilimumab Melanoma NCT01844505 Nivolumab

DOI 10.1186/s40164-019-0138-9

PMID 31312536

发布时间 2022-04-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Experimental hematology & oncology

2019年8卷

14页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma.

Experimental hematology & oncology

相似文献

Experimental hematology & oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma.

Experimental hematology & oncology

相似文献

Experimental hematology & oncology

相关期刊

检索历史清除